To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Nabilone safe and effective in pain reduction in combination with gabapentin compared to placebo

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
September 2018

Nabilone safe and effective in pain reduction in combination with gabapentin compared to placebo

Vol: 7| Issue: 9| Number:26| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial

Pain Med. 2015 Jan;16(1):149-59. doi: 10.1111/pme.12569

Contributing Authors:
D Turcotte M Doupe M Torabi A Gomori K Ethans F Esfahani K Galloway M Namaka

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Current convention in managing neuropathic pain (NPP) from relapsing-remitting multiple sclerosis (RRMS) often involves gabapentin (GBP) as first-line therapy and cannabis (CB) as an alternative, had other therapies not worked. The combination of GBP and CB has not been explored. In this study, 15 patients with NPP from RRMS and still experience considerable pain after a stable dosage of GBP were ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue